XBI Stock Recent News

Launched on 01/31/2006, the SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.

Jared Holz, Mizuho healthcare sector specialist, joins 'Squawk on the Street' to discuss how Holz broadly sees the biotechnology sector, what distills the winners from losers in the healthcare space, and the innovation taking place in healthcare.

The SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.

September was the worst month for equities in 2023, but that's simply creating buying opportunities for the long-term investor. I added to four different positions in my CEF portfolio this month, though they are all familiar names that I've already owned. The theme this month was once again avoiding taking on leveraged funds, and none of the four funds take on any leverage in the form of borrowings.

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched on 01/31/2006.

The best healthcare ETFs patch investors into an area of the market that offers both defensive properties and long-term growth.

A smart beta exchange traded fund, the SPDR S&P Biotech ETF (XBI) debuted on 01/31/2006, and offers broad exposure to the Health Care ETFs category of the market.

Launched on 01/31/2006, the SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.

ARKG: Outperforming XBI, Reasonably Valued With Technical Upside Potential In 2H

Artificial Intelligence stands to revolutionize drug discovery and manufacturing in the biotech industry, promising faster, cost-effective processes, which could greatly benefit biotech investors. The SPDR S&P Biotech ETF, an equal-weighted fund with broad industry exposure, presents an attractive investment vehicle to leverage these AI-driven changes. Despite recent downturns in the biotech sector and XBI's specific exposure to smaller, speculative biotech firms, long-term trends and AI advancements suggest a strong rebound.